医療従事者の為の最新医療ニュースや様々な情報・ツールを提供する医療総合サイト

Axonics® Sacral Neuromodulation System Receives Marketing Approval in Australia

2018年01月08日 PM05:00
このエントリーをはてなブックマークに追加


 

IRVINE, Calif.

Axonics Modulation Technologies, Inc. announced today that it received marketing approval from the Australian Department of Health, Therapeutic Goods Administration (TGA) for the first rechargeable Sacral Neuromodulation (r-SNM™) System® to treat Overactive Bladder (OAB), Fecal Incontinence and Urinary Retention.

This approval confirms that the Axonics r-SNM System meets all of the Australian Medical Devices Regulations for Active Implantable Medical Devices and enables commercialization throughout Australia.

“Australian TGA approval provides Axonics with another important marketing approval. Along with our European CE mark and Health Canada approval, this gives us the ability to sell our product in three significant international territories while we complete our U.S. pivotal study,” said Raymond W. Cohen, Chief Executive Officer of Axonics.

Over five million people, or approximately 20% of the Australian population, experience bladder or bowel control problems, many of which are not provided with a suitable therapeutic option. Urinary incontinence tops the list with up to 37% of women affected (Australian Institute of Health and Welfare report, 2006).

In the U.S. and Europe, OAB affects an estimated 85 million adults with another 40 million reported to suffer from fecal incontinence. SNM therapy is an effective and durable treatment that has been widely used and reimbursed for the past two decades accounting for an estimated $700 million in revenue in 2017. SNM is the only OAB treatment with proven clinical superiority to standard medical therapy and OAB patients who receive SNM report significantly higher quality of life than patients undergoing drug treatment.

About Axonics Modulation Technologies, Inc.

Axonics, based in Irvine, CA, is a privately-held venture backed company that has developed a novel implantable neuromodulation technology for patients with urinary and bowel dysfunction and can be further directed towards other clinical indications. The Axonics r-SNM system includes a miniaturized rechargeable implantable stimulator qualified to function at least 15 years, a charging system optimized for reduced charge time without overheating, a patient-friendly remote control and an intuitive clinician programmer that facilitates the lead placement procedure and programming.

During 2016, the Axonics r-SNM system gained regulatory approval in Europe and Canada for the treatment of overactive bladder, urinary retention, and fecal incontinence. In November 2017, the U.S. Food & Drug Administration granted an Investigational Device Exemption to allow Axonics to conduct a pivotal study designed to gain FDA pre-market approval in the United States.

For more information, visit the Company’s website at www.axonicsmodulation.com

View source version on businesswire.com: http://www.businesswire.com/news/home/20180108005360/en/

CONTACT

Company Contact
Axonics Modulation Technologies, Inc.
Dan
Dearen, +1-949-396-6322
Chief Operating & Financial Officer
ddearen@axonicsmodulation.com
or
Investor
& Media Contact

W2Opure
Matt Clawson, +1-949-370-8500
mclawson@W2Ogroup.com

Related Posts Plugin for WordPress, Blogger...
 

同じカテゴリーの記事 

  • ティルレイが国際諮問委員会の設立を発表
  • Celltrion and Teva Announce FDA Approval of HERZUMA® (trastuzumab-pkrb), a Biosimilar to HERCEPTIN®, for the Treatment of HER2-Overexpressing Breast Cancer for Certain Indications
  • Takeda Receives Positive CHMP Opinion for ADCETRIS® (brentuximab vedotin) for the Treatment of Adult Patients with Previously Untreated CD30+ Stage IV Hodgkin Lymphoma in Combination with AVD
  • Tilray®宣布成立国际顾问委员会
  • 武田和纽约科学院宣布2019年度科学创新者奖获奖人